Delee

Blood testing device for early diagnosis of cancer and treatment…

Y CombinatorWinter 2017ActiveHealthcareDiagnosticsMedical DevicesDiagnostics

What they do

Problem

Cancer is often diagnosed late and clinicians lack easy ways to monitor treatment response non-invasively.

Solution

A blood-testing device that isolates and analyzes circulating tumor cells for early cancer diagnosis and treatment monitoring.

Who it's for

Hospitals, oncology clinics, and clinical laboratories that perform cancer diagnostics and monitoring.

Founders

Liza Velarde

Founder

Co-Founder and acting CEO at Delee Corp. Velarde has been responsible for the development and execution of the company's strategic plans. Velarde's outstanding work has been highly regarded by international institutions such as Cartier Women's Initiative Awards and WeXchange (from the Inter-American Development Bank). She also lead and supervised the development of the Zen FluidicsTM scientific line, a group of products that enables researchers to develop their own microfluidic applications.

LinkedIn · X